卵巢癌是常見的婦科癌症之一，由於卵巢癌在早期沒有明顯的症狀，所以大部分的病人發現是卵巢癌的時候，通常已經是晚期了，病人通常都會伴隨著腹水的產生，且腹水中存在有癌細胞，此時的癌細胞都是比較惡性的。但是，並不是只有卵巢癌會伴隨著腹水的產生，像是肝硬化、胰臟炎、胃癌等疾病都會產生腹水。因此，如果能夠找出一個較專一的卵巢癌的標記，相信對於卵巢癌的診斷及治療都將有所改善。在本研究中，我們利用從打入人類卵巢癌細胞株IGROV1的NOD/SCID老鼠產生之腹水中分離出來的癌細胞，IGROV1-MA，建立能有效產生腹水的動物模式，並且分析了IGROV1-MA與其原始細胞IGROV1的特性，從細胞的形態、生長速率、懸浮球體形成、細胞群落生成、抗藥性等實驗結果得知，IGROV1-MA可能是比較惡性的卵巢癌細胞。之後，利用我們所建構出來的動物模式產生之腹水，以M13噬菌體呈現技術篩選出與IGROV1-MA具有高親和性的胜肽，並且經由DNA定序得知胜肽序列。我們也利用流式細胞儀比較篩選下來的胜肽與許多不同種類的細胞其親和性和專一性，證實篩選出來的胜肽確實比較會接在IGROV1-MA上。本研究篩選出來的胜肽也許是一個新的卵巢癌標記，利用這個新的標記或許可更快速的診斷出病人是否是因為卵巢癌導致有腹水產生，另外，也可以利用這個與卵巢癌細胞專一結合的胜肽發展成一個有力的治療工具，像是將抗癌藥物包裹在脂質體(liposome)內，再將胜肽接在脂質體的表面，以一個較專一的方式去攻擊癌細胞，減低以往治療的副作用。

Ovarian cancer is one of the common gynecologic cancers. There are few specific symptoms appeared in the early-stage ovarian cancer. Most ovarian cancer patients are diagnosed at the advanced stage with widely metastasis. Moreover, the patients who are at late stage accompany malignant cancer cells in their ascites. The patients of many diseases such as hepatocirrhosis, pancreatitis, and gastric cancer may accompany with ascites production. Therefore, to find a more specific ovarian cancer marker should be desirable to improve the diagnosis and therapy in ovarian cancer. In this study, we used IGROV1-MA that is isolated from the ascites of NOD/SCID mice with injecting a human ovarian cancer cell line, IGROV1, to establish an animal model to obtained ovarian cancer cells that could effectively produce malignant ascites. We analyzed the cell properties between IGROV1 and IGROV1-MA. In our results of cell morphology, proliferation rate, sphere forming ability, colony formation assay and drug resistance, IGROV1-MA may be a more malignant ovarian cancer cells than IGROV1. Then we used M13 phage display technology to performe five rounds biopanning against the ascetic ovarian cancer cells in vivo and obtained some phages which have high affinity for IGROV1-MA cells. We identified the sequence of peptides by DNA sequencing. We analyzed the affinity and specificity of selected peptides to several different kinds of cells by using flow cytometry, and demonstrated the selected peptides with the highest affinity and specificity to IGROV1-MA cells. The peptide may be a new marker for ovarian cancer. We could confirm the patients accompany with ascites production whether have ovarian cancer by this marker. In the future, we could develop a powerful therapeutic tool by conjugating this peptide that has high affinity and high specificity against ovarian cancer cells to liposomes which have been packaged with anti-cancer drugs. Therefore, it not only could reduce the side effect of drugs, but also enhance the efficacy of treatment.

Stephen A. Cannistra. Cancer of the Ovary. N Engl J Med 2004; 351: 2519-29.

John K. Chann et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncology 2008; 109: 370–376.

MKY Siu et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 2012; 1–10.

Larry E. Puls et al. The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer. Gynecologic Oncology 1996; 61: 109–112.

N Russo et al. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene 2012; 1–12.

Ruei-Min Lu et al. Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging. PLoS ONE 2013; 8(6): e66128.

Yong-Li Qin et al. Identification of a linear B-cell epitope within the Bluetongue virus serotype 8 NS2 protein using a phage-displayed random peptide library. 2013. (article in press)

Tariq Bashir et al. Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice. PLoS ONE 2012; 7(10): e47741.

M Figini et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy 2003; 10: 1018–1025.

Takafumi Kuroda et al. ALDH1-High Ovarian Cancer Stem-Like Cells Can Be Isolated from Serous and Clear Cell Adenocarcinoma Cells, and ALDH1 High Expression Is Associated with Poor Prognosis. PLoS ONE 2013; 8(6): e65158.

Michael Dean et al. Tumour Stem Cells and Drug resistance. Nature Reviews Cancer 2005; 5: 275-284.

CR Jeter et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 1–13.

MKY Siu et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 2012; 1–10.

Marta Palafox et al. RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. Cancer Res 2012; 72: 2879-2888.

Ruei-Min Lu et al. Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging. PLoS ONE 2013; 8(6): e66128.

Tong-Young Lee et al. Peptide-Mediated Targeting to Tumor Blood Vessels of Lung
Cancer for Drug Delivery. Cancer Res 2007; 67: 10958-10965.